141 related articles for article (PubMed ID: 35428504)
1. Imaging and Laboratory Workup for Melanoma.
Kaleem A; Patel N; Chandra SR; Vijayaraghavan RL
Oral Maxillofac Surg Clin North Am; 2022 May; 34(2):235-250. PubMed ID: 35428504
[TBL] [Abstract][Full Text] [Related]
2. Clinical Value of PET/CT in Staging Melanoma and Potential New Radiotracers.
Annunziata S; Laudicella R; Caobelli F; Pizzuto DA; Aimn Working Group Y
Curr Radiopharm; 2020; 13(1):6-13. PubMed ID: 31749438
[TBL] [Abstract][Full Text] [Related]
3. 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.
Wieder HA; Tekin G; Rosenbaum-Krumme S; Klode J; Altenbernd J; Bockisch A; Nagarajah J
Nuklearmedizin; 2013; 52(5):198-203. PubMed ID: 23969722
[TBL] [Abstract][Full Text] [Related]
4. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of imaging studies for initial staging of T2b to T4b melanoma patients: A cross-sectional study.
Riquelme-Mc Loughlin C; Podlipnik S; Bosch-Amate X; Riera-Monroig J; Barreiro A; Espinosa N; Moreno-Ramírez D; Giavedoni P; Vilana R; Sánchez M; Vidal-Sicart S; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2019 Dec; 81(6):1330-1338. PubMed ID: 31163236
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma.
Veit-Haibach P; Vogt FM; Jablonka R; Kuehl H; Bockisch A; Beyer T; Dahmen G; Rosenbaum S; Antoch G
Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):910-8. PubMed ID: 19156409
[TBL] [Abstract][Full Text] [Related]
7. Melanoma patient imaging in the era of effective systemic therapies.
Stodell M; Thompson JF; Emmett L; Uren RF; Kapoor R; Saw RPM
Eur J Surg Oncol; 2017 Aug; 43(8):1517-1527. PubMed ID: 28625798
[TBL] [Abstract][Full Text] [Related]
8. [Malignant melanoma: diagnostic value of F-18 FDG positron emission tomography].
Aigner RM; Schwarz T; Richtig E
Wien Med Wochenschr; 2002; 152(11-12):286-8. PubMed ID: 12138657
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography/computed tomography in melanoma.
Bourgeois AC; Chang TT; Fish LM; Bradley YC
Radiol Clin North Am; 2013 Sep; 51(5):865-79. PubMed ID: 24010910
[TBL] [Abstract][Full Text] [Related]
10. Use of Preoperative PET/CT Staging in Sentinel Lymph Node-Positive Melanoma.
Scheier BY; Lao CD; Kidwell KM; Redman BG
JAMA Oncol; 2016 Jan; 2(1):136-7. PubMed ID: 26401901
[No Abstract] [Full Text] [Related]
11. Clinical Diagnosis and Classification: Including Biopsy Techniques and Noninvasive Imaging.
Vakharia KT
Clin Plast Surg; 2021 Oct; 48(4):577-585. PubMed ID: 34503718
[TBL] [Abstract][Full Text] [Related]
12. TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.
Naeser Y; Helgadottir H; Brandberg Y; Hansson J; Bagge RO; Elander NO; Ingvar C; Isaksson K; Flygare P; Nilsson C; Jakobsson F; Del Val Munoz O; Valachis A; Jansson M; Sparring C; Ohlsson L; Dyrke U; Papantoniou D; Sundin A; Ullenhag GJ
BMC Cancer; 2020 Dec; 20(1):1197. PubMed ID: 33287744
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
14. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma.
Twycross SH; Burger H; Holness J
S Afr J Surg; 2019 Sep; 57(3):44-49. PubMed ID: 31392864
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma.
Podlipnik S; Moreno-Ramírez D; Carrera C; Barreiro A; Manubens E; Ferrandiz-Pulido L; Sánchez M; Vidal-Sicart S; Malvehy J; Puig S
Br J Dermatol; 2019 May; 180(5):1190-1197. PubMed ID: 29876940
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients.
Swetter SM; Carroll LA; Johnson DL; Segall GM
Ann Surg Oncol; 2002 Aug; 9(7):646-53. PubMed ID: 12167578
[TBL] [Abstract][Full Text] [Related]
17. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis.
Xing Y; Bronstein Y; Ross MI; Askew RL; Lee JE; Gershenwald JE; Royal R; Cormier JN
J Natl Cancer Inst; 2011 Jan; 103(2):129-42. PubMed ID: 21081714
[TBL] [Abstract][Full Text] [Related]
18. PET/CT in malignant melanoma: a two-tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CT.
Matiszick A; Völker C; Garbe C; Gutzmer R; Forschner A; Wagner G; Franzius C; Czech N; Schüssler F; Meier F; Sachse MM
J Dtsch Dermatol Ges; 2021 Jun; 19(6):852-862. PubMed ID: 33890389
[TBL] [Abstract][Full Text] [Related]
19. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
Kumar R; Alavi A
Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
